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ENVENOMATIONS by the snake Bothrops asper are
characterized by prominent local tissue damage (i.e.
myonecrosis), blistering, hemorrhage and edema.
Various phospholipases A2 and metalloproteinases
that induce local pathological alterations have been
purified from this venom. Since these toxins induce a
conspicuous inflammatory response, it has been
hypothesized that inflammatory mediators may con-
tribute to the local pathological alterations described.
This study evaluated the local production of cytokines
and matrix metalloproteinases (MMPs) as a con-
sequence of intramuscular injections of an Asp-49
myotoxic phospholipase A2 (myotoxin III (MT-III))
and a P-I type hemorrhagic metalloproteinase (BaP1)
isolated from B. asper venom. Both enzymes induced
prominent tissue alterations and conspicuous incre-
ments in interleukin (IL)-1 b , IL-6 and a number of
MMPs, especially gelatinase MMP-9, rapidly after
injection. In contrast, no increments in tumor necro-
sis factor- a (TNF- a ) and interferon-g were detected.
In agreement, MT-III and BaP1 did not induce the
synthesis of TNF- a by resident peritoneal macro-
phages in vitro. Despite the conspicuous expression
of latent forms of MMPs in muscle, evidenced by
zymography, there were no increments in activated
MMP-2 and only a small increase in activated MMP-9,
as detected by a functional enzymatic assay. This
suggests that MMP activity was regulated by a highly
controlled activation of latent forms and, probably,
by a concomitant synthesis of MMP inhibitors. Since
no hemorrhage nor dermonecrosis were observed
after injection of MT-III, despite a prominent increase
in MMP expression, and since inflammatory exudate
did not enhance hemorrhage induced by BaP1, it is
suggested that endogenous MMPs released in the
tissue are not responsible for the dermonecrosis and
hemorrhage characteristic of B. asper envenomation.
Moreover, pretreatment of mice with the peptidomi-
metic MMP inhibitor batimastat did not reduce myo-
toxic nor edema-forming activities of MT-III, suggest-
ing that MMPs do not play a prominent role in the
pathogenesis of these effects in this experimental
model. It is concluded that MT-III and BaP1 induce a
local inflammatory response associated with the
synthesis of IL-1 b , IL-6 and MMPs. MMPs do not seem
to play a prominent role in the acute local patho-
logical alterations induced by these toxins in this
experimental model.
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Introduction
Envenomations induced by the bites of snakes from
the family Viperidae are characterized by drastic local
tissue damage involving necrosis of muscle, blistering,
hemorrhage and a prominent inflammatory res-
ponse, associated with edema, pain and a leukocyte
infiltrate.1–3 The pathogenesis of these alterations is
rather complex, involving both the direct action of
tissue-damaging toxins present in the venom and the
participation of endogenous mediators that might
contribute to such alterations. However, the precise
role of each of these elements in venom-induced local
effects has not been fully elucidated.
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Bothrops asper is the most important poisonous
snake in Central America, where it inflicts more than
50% of snakebites.4 Its venom induces prominent
local tissue damage.1,5Acute muscle damage is caused
by a group of highly basic phospholipases A2 and
phospholipase A2 homologs that bind to and disrupt
skeletal muscle cell plasma membrane, promoting a
calcium influx that culminates in irreversible cell
damage.5,6 Hemorrhage is induced by the action of
zinc-dependent metalloproteinases that hydrolyze
proteins of the basement membrane of capillaries. As
a consequence, endothelial cells are affected, with
disruption of the capillary wall and extravasation.7–10
Metalloproteinases are also responsible for blistering,
probably by degrading basement membrane compo-
nents at the dermal–epidermal junction.11
Besides the direct action of venom phospholipases
A2 and metalloproteinases, B. asper envenomations
are also characterized by the synthesis and release of
a number of endogenous mediators that promote
edema and pain.12–14 However, little is known on the
local synthesis of cytokines and matrix metalloprotei-
nases (MMPs) in B. asper envenomations. Previous
investigations have documented elevated serum lev-
els of some cytokines after experimental injections of
various Bothrops sp. venoms,15–17 and increments in
MMPs in skin and exudates after intramuscular
injection of B. asper P-I type hemorrhagic metal-
loproteinase BaP1 were described.11 Furthermore, it
was observed that venom metalloproteinases are able
to release tumor necrosis factor-a (TNF-a) from its
recombinant precursor in vitro.18 Cytokines and
MMPs are important mediators of tissue damage and
inflammation in a variety of pathologies,19,20 and they
may play a role in venom-induced local alterations,
enhancing the tissue damage initiated by venom
components, a hypothesis that needs to be
addressed.
The aim of the present work was to determine
whether cytokine and MMP levels increase in muscle
tissue injected with two tissue-damaging toxins from
B. asper venom, myotoxic phospholipase A2 myo-
toxin III (MT-III) and hemorrhagic metalloproteinase
BaP1. Furthermore, the possible role of MMPs in the
pathogenesis of acute local tissue damage was investi-
gated in this experimental model.
Materials and methods
Toxins
MT-III and metalloproteinase BaP1 were isolated from a
venom pool obtained from more than 40 adult
specimens of B. asper collected in Costa Rica and kept
at the Serpentarium of Instituto Clodomiro Picado. MT-
III was isolated by ion-exchange chromatography on
CM-Sephadex C-25,21,22 whereas BaP1 was purified by
ion-exchange chromatography on CM-Sephadex C-25,
gel filtration on Sephacryl S-200 and affinity chroma-
tography on Affi-gel Blue.11,23 Homogeneity of the
enzymes was demonstrated by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis under reduc-
ing conditions.24
Determination of increments in MMPs
Groups of four Swiss mice (18–20 g) were injected
intramuscularly (i.m.), in the right gastrocnemius,
with 60mg of either MT-III or BaP1, dissolved in 60ml
of sterile, endotoxin-free saline solution (0.15 M
NaCl). All animal experiments in this study were
approved by the Animal Ethical Committee of the
University of Costa Rica. Control mice received 60ml
of sterile saline solution alone. At various time
intervals, mice were killed by CO2 inhalation, and the
injected gastrocnemius were dissected out and
homogenized in 2.0 ml of endotoxin-free saline solu-
tion using a PT 10/35 homogenizer (Brinkmann
Instruments Co., New York, USA). Muscle homoge-
nates were centrifuged at 6000 ´ g for 5 min and the
supernatants collected, stored at –70°C and used
within the following week. The protein concentration
of all samples was assessed according to Spector25 in
order to load the same amount of protein in the gels.
Metalloproteinase activity was visualized by zymog-
raphy, according to the procedure of Herron et al.,26
with the modifications described by Rucavado et al.11
Briefly, electrophoreses were performed at 100 V in a
Mini-Protean cell (Bio-Rad, CA, USA), using a 5–20%
gradient SDS-polyacrylamide gel containing Type A
gelatin (Sigma Chemical Co, St Louis, MO, USA).
Molecular weight markers were included. After a
washing step with 2.5% Triton X-100 with shaking for
30 min, gels were incubated at 37°C for 18 h in
50 mM Tris–HCl (pH 8.0) buffer, containing 5 mM
CaCl2 and 20 mg/dl of sodium azide. Gels were then
stained with 0.5% Coomassie Blue R-250 in acetic
acid:isopropyl alcohol:water (1:3:6) and destained
with distilled water. Gels run under identical condi-
tions were incubated in the presence of 20 mM
ethylenediamine tetraacetic acid (EDTA) to inhibit
metalloproteinases.
Since the zymography assay described detects both
latent and active MMPs, as well as those forming
complexes with TIMPs, additional experiments were
performed to estimate the concentration of latent and
active MMPs in muscle homogenates. Active MMP-2
and MMP-9 were quantitated by the functional assay
system Biotrak (codes 2630 and 2631; Amersham
Pharmacia Biotech, UK). In conditions where
p-aminophenylmercuric acetate (APMA) is not added
to the enzyme, this assay detects only active MMPs.
Addition of APMA allows detection of both latent and
active forms. Homogenate samples, standardized by
protein concentration,25 were added to microplate
wells in which either anti-MMP-2 or anti-MMP-9
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antibodies had been adsorbed. After an overnight
incubation at 4°C and a washing step, the pro-enzyme
form of a detection enzyme was added, together with
its substrate, and the plates were incubated at 37°C.
Active MMPs cleave this pro-enzyme, activating it to
hydrolyze its substrate with the formation of a colored
product. Absorbances at 405 nm were recorded in a
Multiskan microplate reader and enzymatic activitiy
was determined on the basis of a standard curve
prepared with purified MMP-2 and MMP-9.
Quantification of cytokine levels
For quantification of cytokine levels in muscle, the
same homogenization protocol already described was
followed. TNF-a, interleukin (IL)-1b, interferon-g
(IFN-g) and IL-6 were quantitated by enzyme-immu-
noassays (Quantikine™ M; R & D Systems, MN, USA)
following the manufacturer’s instructions. TNF-a was
also quantitated by a cytotoxic assay using the
fibroblast cell line L-929,27 with the modifications
described by Petricevich et al.17 Briefly, monolayers
of L-929 cells were seeded in microtiter plates and
incubated in a humidified air atmosphere with 5%
CO2 at 37°C for 18 h. Then, samples of muscle
homogenates in RPMI-1640, containing 1.0mg/ml of
actinomycin D, were added. After incubation for 18 h
at 37°C, supernatants were removed and viable cells
were assessed after fixation and staining with crystal
violet (0.2% in 20% methanol). Negative controls
included cells incubated with RPMI medium. A
standard curve was prepared with known concentra-
tions of recombinant TNF-a.
Effects of BaP1 on macrophages in vitro
Resident, non-elicited macrophages were collected
from anesthetized Swiss mice by lavage of the
peritoneal cavity with sterile 0.15 M NaCl solution.
Cells were counted in a hemocytometer, centrifuged
and pelleted. Macrophages were resuspended in
RPMI medium and applied to plates (1.5 ´ 105cells/
well) and incubated with MT-III or BaP1 (6.25, 12.5
and 25.0mg/ml) for 60 min at 37°C under a 95% air,
5% CO2 atmosphere. In some experiments, super-
natants of macrophage cultures were assessed for
the presence of TNF-a by the cytotoxic assay on
L929 cells already described. An additional step was
introduced in some experiments to increase the
sensitivity of the assay. After incubation with toxins,
macrophages were harvested and 2 ´ 104 cells,
suspended in RPMI medium, were directly applied
on monolayers of L929 cells. After 24 h of incubation
at 37°C, the viability of L929 cells was assessed as
already described. Recombinant TNF-a and anti-TNF-
a antibodies were used in some controls to assure
that the cytotoxic effect was indeed caused by this
cytokine.
Histological studies
To determine whether treatment with MT-III or BaP1
induces skin lesions, mice were injected with 60mg
of these toxins i.m. in the gastrocnemius, as descri-
bed, and were killed at 1 or 3 h. The skin overlying the
injected area was dissected out, cut into small pieces
and fixed in Karnovsky’s fixative (2.5% glutaralde-
hyde, 2% paraformaldehyde in 0.1 M phosphate
buffer; pH 7.2). Postfixation was performed with 1%
osmium tetroxide. Afterwards, samples were dehy-
drated in ethanol and embedded in Spurr resin.7 One
micrometer sections were cut and stained with
toluidine blue for histological observation.
Inhibition by the peptidomimetic hydroxamate
batimastat
To determine whether MMPs synthesized after MT-III
injection contribute to muscle damage and edema,
mice were pretreated with an intraperitoneal (i.p.)
injection of the peptidomimetic inhibitor batimastat
(BB-94; British Biotech Pharmaceuticals Ltd., Oxford,
UK). Batimastat suspension was prepared by sonica-
tion in phosphate-buffered saline solution (PBS) (pH
7.2), containing 0.01% Tween 80 and injected intra-
peritoneally at a dose of 30 mg/kg. This dose was
selected since it has been used in previous studies
dealing with the effect of this inhibitor in experimental
cancer models,28 in which a systemic concentration
above the IC50 values for MMPs was reached. Three
hours after batimastat administration, mice were
injected with MT-III either i.m. (50mg), in the
gastrocnemius, or subcutaneously (20mg), in the
footpad, for the assessment of myonecrosis and
footpad edema, respectively.11,29 Myotoxicity was
evaluated 3 h after MT-III injection by determining the
plasma creatine kinase (CK) activity.30 Edema was
evaluated by measuring the increase in footpad
thickness at various time intervals after toxin injection
with the aid of a low-pressure spring caliper.15,29
Potentiation of BaP1-induced hemorrhage and
dermonecrosis by inflammatory exudate
Inflammatory exudate was collected from mice 3 h
after i.m. injection of 60mg of MT-III in the right
gastrocnemius. Animals were killed and a small
incision was made in the skin overlying the injected
muscle. Exudate was collected into heparinized
capillary tubes and centrifuged at 2000 ´ g for 5 min.
For studying the possible effect of MMPs present in
inflammatory exudate on the hemorrhagic and dermo-
necrotic activities of BaP1, groups of five mice were
injected intradermally, in the abdominal region, with
either BaP1 plus PBS, BaP1 plus exudate, or exudate
plus PBS. Animals were killed after either 2 or 72 h for
quantification of hemorrhagic and necrotizing lesions,
respectively.31,32 Hemorrhagic and necrotic areas
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were measured in the inner side of the skin. Then,
hemorrhagic areas were cut and placed into 2 ml of
distilled water overnight for elution of hemoglobin.
Tubes were centrifuged and the absorbances of
supernatants recorded at 540 nm as a quantitative
assessment of hemoglobin concentration.
Statistical analysis
The significance of the differences between the mean
values of two experimental groups was determined
by the Student’s t-test, using p < 0.05 to establish
significance.
Results
Studies on MMPs and cytokines in muscle
Samples of muscle homogenates obtained from mice
injected with saline solution showed two main
proteolytic bands of 100 and 60 kDa when analyzed
by zymography (Fig. 1). A conspicuous increment in
the intensity of the 100 kDa band was observed in
samples obtained 1 and 6 h after MT-III and BaP1
injections (Fig. 1). In addition, bands of 270, 230, 135,
115, 74, 65 and 57 kDa were also detected. When
incubations were carried out in the presence of
EDTA, proteolytic activity was abrogated. There were
no qualitative differences in the zymographic pattern
between samples obtained from mice injected with
MT-III and BaP1.
Enzymatic activity of MMP-2 and MMP-9 was
quantified in muscle homogenates by a functional
assay that includes an antibody-binding step, followed
by a quantitative enzymatic determination. When
compared with homogenates from mice injected with
saline solution, no increments in either latent or
activated forms of MMP-2 were detected. In contrast,
both toxins induced increments in MMP-9 activity.
When only the active form of the enzyme was
detected, activity was: BaP1, 1 h, 17 ± 2 ng/g tissue;
BaP1, 6 h, 8 ± 3 ng/g; MT-III, 1 h, 17 ± 2 ng/g; MT-III,
6 h, activity below the detection limit of the assay.
When both latent and active forms were quantified
(i.e. when APMA was included in the assay), activity
increased significantly: BaP1, 1 h, 180 ± 5 ng/g tissue;
BaP1, 6 h, 78 ± 28 ng/g; MT-III, 1 h, 789 ± 181 ng/g; MT-
III, 6 h, 65 ± 0.2 ng/g. Thus, most of the expressed
MMP-9 was in the latent form at these time intervals.
A prominent increment in muscle levels of IL-1b
and IL-6 was observed early after injection of MT-III
and BaP1, higher levels being induced by myotoxin
administration (Fig. 2). Maximum levels were attained
between 3 and 6 h, decreasing afterwards. In contrast,
no evidence of TNF-a nor IFN-g increments were
detected in muscle homogenates by the enzyme
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FIG. 1. Zymograms of muscle homogenates from mice
injected i.m. with 60mg of MT-III or BaP1. Gelatinase activity
was assessed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (5–20% acrylamide gradient) containing 1%
type A gelatin. Muscle homogenates after injection of: (1)
BaP1, 1 h; (2) BaP1, 6 h; (3) MT-III, 1 h; (4) MT-III, 6 h; (5) saline.
Molecular weight markers are depicted to the left.
FIG. 2. Increments of IL-1b and IL-6 in muscle homogenates
after i.m. injection of 60mg of MT-III or BaP1, dissolved in
60ml of saline solution. Control mice received saline solution
alone. Mice were injected in the right gastrocnemius and, at
various time intervals, they were killed and the injected
muscle was excised, weighed and homogenized in 2.0 ml of
saline solution. After centrifugation, cytokine levels were
quantitated by enzyme-linked immunosorbent assay (see
Materials and methods). Results are presented as mean ±
standard deviation (n = 4).
immunoassay utilized. In these cases, cytokine con-
centration did not differ significantly from those of
saline-injected muscle and were below the detection
limit of the assay. In agreement with this, TNF-a was
not detected in muscle homogenates by the cytotoxic
assay on fibroblasts L929.
Effect of BaP1 on TNF-a production by
macrophages in vitro
Neither MT-III nor BaP1 induced the synthesis of TNF-
a by resident non-elicited peritoneal macrophages on
incubation in vitro for 60 min, as evidenced by lack of
cytotoxicity of supernatants on L929 cells (results not
shown). To increase the sensitivity of the assay,
macrophages that had been incubated with toxins
were harvested and directly applied to cultures of
L929 cells. Again, negative results were obtained at
the doses tested.
Histological studies
Pathological alterations induced by B. asper myotox-
ins and BaP1 in muscle have been previously descri-
bed in detail.6,10 In the present study, we investigated
the alterations induced by these toxins in the skin.
Control mice injected with saline solution showed a
normal morphology, with the characteristic structure
of epidermis, dermis and hypodermis. In contrast,
samples from mice injected with BaP1 showed
prominent hemorrhage and inflammation in the
hypodermis and dermis, together with the formation
of blisters, characterized by the separation of epi-
dermis from the underlying dermis, in agreement
with previous observations11 (Fig. 3A). Skin samples
from mice injected with MT-III showed only a mild
inflammatory reaction in the dermis. No evidence of
blisters were observed (Fig. 3B), although there was
necrosis of the panniculus carnosus muscle (not
shown), indicating that the toxin reached the skin.
Inhibition by batimastat and effect of exudate
on BaP1-induced hemorrhage
Administration of batimastat by the i.p. route 3 h
before MT-III injection did not decrease the extent of
edema induced by this myotoxin (Table 1). Regarding
myotoxicity, plasma CK levels of mice injected with
MT-III alone were 4051 ± 268 U/l, CK levels of MT-III-
injected mice that had been pretreated with batima-
stat were 3880 ± 297 U/l, and CK levels of MT-III-
injected mice pretreated with batimastat and
receiving an additional local injection of batimastat
were 3524 ± 399 U/l. None of these treatments
promoted a significant reduction of myotoxicity (p >
0.05). Inflammatory exudate collected 3 h after MT-III
injection, having a protein concentration of 4.00 ±
0.24 g/dl, did not increase nor reduce the extent of
hemorrhage induced by intradermal injections of
BaP1 (Table 2). Inflammatory exudate itself lacked
hemorrhagic activity in these assays. Moreover, mice
receiving an intradermal injection of BaP1 alone
presented a necrotic skin lesion of 3.73 ± 0.15 mm (n
= 3) 3 days after injection. When BaP1 was co-injected
with exudate, the diameter of the necrotic lesion was
3.57 ± 0.15 mm (p > 0.05 when compared with BaP1
alone), exudate alone being devoid of necrotizing
effect.
Discussion
A conspicuous increase in IL-1b and IL-6, as well as a
prominent increment in the expression of MMP-9,
were observed in gastrocnemius muscle injected with
MT-III and metalloproteinase BaP1. Local tissue
pathology induced by B. asper venom, and probably
by other crotaline snake venoms as well, is mainly
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FIG. 3. Light micrographs of sections of skin from mice
injected i.m. in the gastrocnemius with 60mg of either BaP1
(A) or MT-III (B). Tissue samples were obtained 3 h after
injection, processed and embedded in Spurr resin. Thick
(1mm) sections were stained with toluidine blue. Notice the
presence of hemorrhage in the dermis and the formation of
a blister (Bli) in mice injected with BaP1, whereas no evident
pathological alterations in dermis and epidermis were
observed after injection of MT-III.
characterized by a direct muscle damage induced by
phospholipases A2, and by blistering and microvessel
disruption and bleeding induced by metalloprotei-
nases.5,8,11,33 Interestingly, despite the different tar-
gets and mode of action of these toxins, MT-III and
BaP1 induced a qualitatively similar pattern of cyto-
kine and MMP expression in injected muscle. Thus, it
is likely that muscle tissue responds in a rather
stereotyped fashion to locally acting agents of differ-
ent nature present in snake venoms. Cytokine and
MMP increments are likely to be related since a
variety of cytokines, including TNF-a and IL-1b,
induce MMP expression.20,34
Prominent increments of IL-1b and IL-6 occurred,
whereas no elevations of TNF-a and IFN-g were
detected. In the case of TNF-a, this observation was
corroborated using both an enzyme immunoassay and
a cytotoxicity assay. This lack of correlation between
IL-1b and TNF-a increments might be due to the fact
that the former is produced by a number of different
cells types, such as macrophages, endothelial cells
and other cell types,35,36 whereas TNF-a is mainly
produced by macrophages. Resident macrophages are
present in skeletal muscle,37 but they are not elicited
under normal conditions. Thus, when MT-III and BaP1
are injected, these resident macrophages do not seem
to synthesize levels of TNF-a that could be detected
by the assays performed. In agreement with this
contention, TNF-a was not detected in cultures of
non-elicited resident peritoneal macrophages incu-
bated with these toxins. In contrast with our observa-
tions, Clissa et al.38 described the production of TNF-
a by peritoneal macrophages incubated with
jararhagin, a P-III hemorrhagic metalloproteinase
from B. jararaca venom. This apparent discrepancy
may be related to the type of macrophage used, since
Clissa et al.38 worked with thioglycollate-elicited
macrophages, whereas our experiments were per-
formed with resident, non-elicited cells. It would be
relevant to compare the effect of tissue-damaging
toxins on cytokine production by resident, elicited
and activated macrophages.
Increments in serum levels of IL-6 have been
observed in mice injected with B. asper and B. atrox
venoms.15–17 IL-6 is a major mediator of inflamma-
tion,39 inducing the synthesis of acute-phase proteins
in the liver.40 In addition, IL-6 induces myoblast
proliferation in culture,41 suggesting that the
observed increments in this cytokine may influence
skeletal muscle regeneration after snake venom-
induced myonecrosis. IL-1b plays a number of roles in
inflammation, inducing the expression of adhesion
molecules,42 and the release of leukocyte chemotactic
factors,43 besides altering the functional properties of
endothelial cells.35 IL-1b promotes inflammation after
skeletal muscle injury.44 In addition, these cytokines
induce MMP expression34 and probably contribute to
the synthesis of MMPs observed in our experimental
models, since early increments in these cytokines
correlated with the expression of MMPs. Increments
in the serum levels of a number of cytokines have
been described in patients after snakebite envenoma-
tions.45,46 Thus, cytokines may play a relevant role in
the pathophysiology of these envenomations in
humans.
MMPs constitute a group of more than 20 enzymes,
with the common ability to degrade extracellular
matrix components, that play essential roles in
embryonic development, reproduction, tissue remod-
eling and inflammation.19,20 These enzymes are
usually not constitutively present in cells, being
synthesized as prepro-enzymes and secreted as inac-
tive pro-enzymes by a variety of cell types in
inflammatory processes.19,47 However, a constitutive
expression of MMP-2 has been described for mouse
skeletal muscle,48 in agreement with our observations
in control muscle. Zymography results indicate that a
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Table 1. Lack of inhibition of edema-forming activity of MT-III
by pretreatment with the MMP inhibitor batimastat
Time
(min)
Treatment*
Control Batimastat
0† 1.72 ± 0.15‡ 1.69 ± 0.09
15 3.18 ± 0.08 3.15 ± 0.09
60 2.94 ± 0.09 2.99 ± 0.13
180 2.69 ± 0.07 2.76 ± 0.12
* Mice received an i.p. injection of batimastat (30 mg/kg in PBS-0.01 %
Tween), 3 h afterwards they were injected subcutaneously (s.c.) in the
right footpad with 20mg of MT-III in 50ml of PBS. Control mice
received an i.p. injection of PBS–Tween followed by a s.c. injection of
MT-III as described. Edema is expressed as footpad thickness (mm).
† 0 represents footpad thickness immediately before injection of MT-III.
‡ Mean ± standard deviation (n = 4). No significant differences were
observed at any time interval (p > 0.05).
Table 2. Effect of the inflammatory exudate, obtained from
mice injected with MT-III, on the hemorrhagic activity of
metalloproteinase BaP1*
Treatment Diameter of
hemorrhagic lesions
Absorbance
at 540 nm
PBS 0 0.008 ± 0.002†
PBS + exudate 0 0.009 ± 0.002
BaP1 + PBS 14.5 ± 2.3 mm 0.327 ± 0.165
BaP1 + exudate 13.8 ± 1.9 mm 0.358 ± 0.117
* Groups of mice were injected i.m. with 60mg of MT-III and
inflammatory exudate was collected from underneath the skin 3 h
after injection. Then, groups of four mice were injected intradermally
with either PBS (90ml), PBS (50ml) + exudate (40ml), BaP1 (40mg/50
ml) + PBS (40ml), or BaP1 (40mg/50 ml) + exudate (40ml). Hemorrhagic
activity was assessed 2 h after injection by measuring the diameter of
the hemorrhagic spots. Then, skin samples containing the hemor-
rhagic areas were dissected out and placed into 2 ml of distilled water
overnight for elution of hemoglobin. Tubes were centrifuged and the
absorbances of supernatants recorded at 540 nm as a quantitative
assessment of hemoglobin concentration.
† Mean ± standard deviation (n = 4). The differences between the
mean values of mice receiving BaP1 + PBS and those receiving BaP1
+ exudate were not significant (p > 0.05).
number of MMPs, especially MMP-9, are expressed in
muscle injected with MT-III and BaP1. Bands of 60 and
100 kDa observed in zymography probably corre-
spond to the latent forms of MMP-2 and MMP-9,
respectively, as these molecular masses have been
described for these enzymes in mice.48 High activity
was detected in muscle homogenates when both
latent and active MMP-9 were quantitated, whereas
activity was greatly reduced when only the active
form was quantitated by a specific enzymatic assay.
This strengthens the conclusion that most of the
increment in MMP-9 corresponds to the latent form of
the enzyme. MMP-2 and MMP-9 have been reported to
increase in a variety of pathologies, such as myonecro-
sis,48 chronic inflammation,49 meningitis,50 intra-
cerebral hemorrhage and ischemia,51,52 and acute
lung injury,53 among others. In addition to these two
MMPs, other gelatinolytic bands were observed in
muscle homogenates and exudates in our experi-
mental model, which probably correspond to other
members of the MMP family. We also detected two
bands of 270 and 230 kDa, which might represent
MMP aggregates.54 Although the cellular source of
MMPs was not addressed in this study, it is suggested
that resident macrophages, fibroblasts and endothelial
cells constitute the main sources of MMPs during the
first hours after injection of these toxins.34,53,55,56
In the physiological processes in which MMPs
participate, the balance between MMP expression,
activation and inhibition by TIMPs and other inhibitors
is finely regulated.20 On the contrary, exaggerated or
unregulated expression of MMPs may lead to uncon-
trolled extracellular matrix degradation and tissue
damage, as occurs in chronic wounds.49 Thus, the
question was raised in this study as to whether the
observed increment in MMP expression contributes to
the acute local tissue damage characteristic of B. asper
envenomation. Several lines of evidence strongly
suggest that MMPs do not contribute significantly to
the acute tissue damage induced by MT-III and BaP1
during the first 6 h after injection of the toxins.
Pretreatment with batimastat, a potent MMP inhibitor
having broad specificity, did not reduce the extent of
edema and myonecrosis induced by MT-III. Moreover,
MT-III injection did not induce local hemorrhage nor
blistering, despite the conspicuous increase in MMP-9
expression. Thus, in the case of BaP1, it is suggested
that hemorrhage and blister formation are mainly due
to the direct action of this venom metalloproteinase at
the basement membrane of capillary vessels and the
epidermis. This conclusion is strengthened by the
observation that concomitant injection of BaP1 and
inflammatory exudate containing MMPs induced sim-
ilar hemorrhagic and dermonecrotic lesions when
compared with mice injected with BaP1 alone. In
addition, local injection of inflammatory exudates
obtained from MT-III-injected mice did not induce
dermonecrosis nor hemorrhage.
As evidenced by zymography and by a specific
enzymatic assay, MMPs in muscle homogenates corre-
sponded predominantly to the latent forms, therefore
lacking activity under non-denaturing conditions,
such as those operating in vivo. Thus, the apparent
lack of pathological effects of MMPs in this model
might be associated with the very low concentration
of the active forms of these enzymes in the tissue. It is
likely that MMP activity is finely controlled in our
experimental conditions by keeping most of the
enzymes in their latent form and, probably, by a
parallel expression of TIMPs. As a consequence, free
metalloproteinase activity is maintained under con-
trol. It has been observed that the acute wound
microenvironment, such as that of our model, is
characterized by a controlled balance of MMPs and
their inhibitors, whereas in chronic wounds this
balance is disrupted, with the concomitant increment
in MMP free activity associated with prominent
extracellular matrix degradation and pathology.49,57 It
is therefore likely that MMP expression in our
experimental model is a regulated event that does not
seem to play a prominent role in the acute local tissue
damage induced by these toxins within the first hours
after injection. Instead, MMPs probably participate in
the inflammatory response, by remodeling extrac-
ellular matrix and promoting events associated with
inflammatory cell influx, release of matrix-embedded
growth factors and onset of tissue regeneration. The
role of MMPs in the inflammatory and reparative
processes taking place after the onset of acute local
tissue damage induced by snake venom toxins
remains to be investigated.
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